Related Experiment Video

Updated: Aug 19, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Safety assessment of tamoxifen and toremifene

G M Williams1, A M Jeffrey

  • 1American Health Foundation Valhalla, New York, USA.

Oncology (Williston Park, N.Y.)
|May 1, 1997
PubMed

Insights

Toremifene (Fareston) shows a better safety profile than tamoxifen (Nolvadex) in nonclinical studies. Further human data is needed to confirm toremifene

Area of Science:

  • Pharmacology
  • Toxicology
  • Oncology

Background:

  • Tamoxifen (Nolvadex) and toremifene (Fareston) are widely used antiestrogens.
  • Understanding their safety profiles is crucial for patient care.
  • Previous studies indicate potential safety concerns with tamoxifen.

Purpose of the Study:

  • To review and compare the nonclinical and clinical safety data of tamoxifen and toremifene.
  • To evaluate the genotoxic and carcinogenic potential of both antiestrogens.

Main Methods:

  • Comprehensive review of existing nonclinical (animal) and clinical (human) safety studies.
  • Analysis of genotoxicity and carcinogenicity data for tamoxifen and toremifene.

Main Results:

  • Tamoxifen demonstrated genotoxicity and carcinogenicity in both experimental animals and humans.
  • Toremifene showed some positive genotoxicity findings but was not an initiating carcinogen in animal models.
  • Toremifene exhibits a superior nonclinical safety profile compared to tamoxifen.

Conclusions:

  • Toremifene possesses a more favorable nonclinical safety profile than tamoxifen.
  • Long-term human safety data for toremifene is required to definitively assess its comparative safety.
  • Further research is needed to confirm if toremifene offers improved safety in clinical use.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...